Rezultati - John F. Kokai–Kun

  • Showing 1 - 16 results of 16
Refine Results
  1. 1
    Comparison of Four Methods for Determining Lysostaphin Susceptibility of Various Strains of <i>Staphylococcus aureus</i>

    Comparison of Four Methods for Determining Lysostaphin Susceptibility of Various Strains of <i>Staphylococcus aureus</i> od Caroline M. Kusuma, John F. Kokai–Kun

    Izdano 2005
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Deletion analysis of the Clostridium perfringens enterotoxin

    Deletion analysis of the Clostridium perfringens enterotoxin od John F. Kokai–Kun, Bruce A. McClane

    Izdano 1997
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model

    Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model od John F. Kokai–Kun, Tanya Chanturiya, J J Mond

    Izdano 2007
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice

    Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice od John F. Kokai–Kun, Tanya Chanturiya, James J. Mond

    Izdano 2009
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Lysostaphin Cream Eradicates <i>Staphylococcus aureus</i> Nasal Colonization in a Cotton Rat Model

    Lysostaphin Cream Eradicates <i>Staphylococcus aureus</i> Nasal Colonization in a Cotton Rat Model od John F. Kokai–Kun, S. M. Walsh, Tanya Chanturiya, James J. Mond

    Izdano 2003
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    Lysostaphin Disrupts <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i> Biofilms on Artificial Surfaces

    Lysostaphin Disrupts <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i> Biofilms on Artificial Surfaces od Julie A. Wu, Caroline M. Kusuma, James J. Mond, John F. Kokai–Kun

    Izdano 2003
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    COVID-19 vaccine platforms: Delivering on a promise?

    COVID-19 vaccine platforms: Delivering on a promise? od Mark Verdecia, John F. Kokai–Kun, Maura Kibbey, Sarita Acharya, Jaap Venema, Fouad Atouf

    Izdano 2021
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    Comparison of Western immunoblots and gene detection assays for identification of potentially enterotoxigenic isolates of Clostridium perfringens

    Comparison of Western immunoblots and gene detection assays for identification of potentially enterotoxigenic isolates of Clostridium perfringens od John F. Kokai–Kun, J. Glenn Songer, John R. Czeczulin, Fei Chen, Bruce A. McClane

    Izdano 1994
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  9. 9
    Catalase (KatA) and Alkyl Hydroperoxide Reductase (AhpC) Have Compensatory Roles in Peroxide Stress Resistance and Are Required for Survival, Persistence, and Nasal Colonization in<i>Staphylococcus aureus</i>

    Catalase (KatA) and Alkyl Hydroperoxide Reductase (AhpC) Have Compensatory Roles in Peroxide Stress Resistance and Are Required for Survival, Persistence, and Nasal Colonization in... od Kate Cosgrove, Graham Coutts, Ing‐Marie Jonsson, Andrej Tarkowski, John F. Kokai–Kun, James J. Mond, Simon J. Foster

    Izdano 2006
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  10. 10
    Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial

    Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial od John F. Kokai–Kun, Tracey Roberts, Olivia Coughlin, Chenxiong Le, Heidi Whalen, Ralph W. Stevenson, Vincent J. Wacher, Joseph Sliman

    Izdano 2019
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  11. 11
    The Staphylococcus aureus Surface Protein IsdA Mediates Resistance to Innate Defenses of Human Skin

    The Staphylococcus aureus Surface Protein IsdA Mediates Resistance to Innate Defenses of Human Skin od Simon R. Clarke, Ramlan Mohamed, Bian Li, Alexander F. Routh, John F. Kokai–Kun, James J. Mond, Andrej Tarkowski, Simon J. Foster

    Izdano 2007
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  12. 12
    Characterization of IsaA and SceD, Two Putative Lytic Transglycosylases of <i>Staphylococcus aureus</i>

    Characterization of IsaA and SceD, Two Putative Lytic Transglycosylases of <i>Staphylococcus aureus</i> od Melanie R. Stapleton, Malcolm J. Horsburgh, Emma J. Hayhurst, Lynda Wright, Ing‐Marie Jonsson, Andrej Tarkowski, John F. Kokai–Kun, James J. Mond, Simon J. Foster

    Izdano 2007
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  13. 13
    The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies

    The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies od John F. Kokai–Kun, Tracey Roberts, Olivia Coughlin, Éric Sicard, Marianne Rufiange, Richard N. Fedorak, Christian Carter, Marijke H. Adams, James Longstreth, Heidi Whalen, Joseph Sliman

    Izdano 2017
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  14. 14
    Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections, in Very-Low-Birth-Weight Neonates

    Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevent... od Leonard E. Weisman, Helen Thackray, Joseph A. Garcia‐Prats, Mirjana Nesin, Joseph H. Schneider, Jennifer Fretz, John F. Kokai–Kun, James J. Mond, William G. Kramer, G. Fischer

    Izdano 2009
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  15. 15
    Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection

    Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection od Michael Kaleko, J. Andrew Bristol, Steven Hubert, Todd B. Parsley, Giovanni Widmer, Saul Tzipori, Poorani Subramanian, Nur A. Hasan, Perrti Koski, John F. Kokai–Kun, Joseph Sliman, Annie Jones, Sheila Connelly

    Izdano 2016
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  16. 16
    Identification of In Vivo–Expressed Antigens of<i>Staphylococcus aureus</i>and Their Use in Vaccinations for Protection against Nasal Carriage

    Identification of In Vivo–Expressed Antigens of<i>Staphylococcus aureus</i>and Their Use in Vaccinations for Protection against Nasal Carriage od Simon R. Clarke, Kirsten J. Brummell, Malcolm J. Horsburgh, Philip W. McDowell, Sharifah Aminah Syed Mohamad, Melanie R. Stapleton, Jorge Luis Arroyo-Acevedo, Robert C. Read, Nicholas P. J. Day, Sharon J. Peacock, James J. Mond, John F. Kokai–Kun, Simon J. Foster

    Izdano 2006
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: